Drug Development

A novel drug designed by AI to prevent a crippling side effect of chemotherapy has received dual US and Taiwan regulatory approval, paving the way for human trials.

Beyond oil, Abu Dhabi is building a global life sciences hub. A new partnership with Sanofi to create a Vaccine Innovation Centre is its boldest move yet.

Early trial data for Verastem Oncology's VS-7375 reveals significant anti-tumor activity and a good safety profile, igniting hope for tough-to-treat cancers.

A new partnership integrates AbTherx's elite Atlas™ mouse platform into FairJourney Bio's workflow, promising to slash timelines and boost success rates.

A new book on psilocybin therapy for women signals a strategic shift from clinical data to lived experience, building a new market in the wellness economy.

With a $2.74M grant from The Michael J. Fox Foundation, biotech startup X-tosis is advancing a novel therapy that aims to fix the cell's failing powerhouses.

Decades-old treatments for bladder cancer are failing. Now, a wave of gene and viral therapies is sparking a market revolution and offering new hope.

A new alliance arms AI 'agents' with scientific reasoning and supercomputing power, aiming to make drug development faster, smarter, and more trustworthy.

With a key grant from Breakthrough T1D, MannKind aims its inhaled insulin at children. Is this a life-changing innovation or a high-stakes corporate revival?

A novel drug aims to reverse myelin damage in MS, a feat no current therapy can achieve. But with a recent FDA hold, is Quantum BioPharma's vision a breakthrough or a mirage?

Quoin Pharma's new drug name is a key step, but the path to the first-ever treatment for a rare skin disease reveals the complex interplay of innovation and finance.

A Canadian biotech is developing a novel cancer drug. We look beyond the paid promotions to analyze the science, the strategy, and the high-stakes reality.

SRX Global's investment in ARMR Sciences' long-lasting fentanyl countermeasure signals a paradigm shift from reactive treatment to proactive biodefense.

Haisco's massive licensing deal with Nuvectis for two high-potential drugs isn't just a transaction; it's a signal of a new world order in biotech.

EpiVax's major lab expansion signals a pivotal shift in medicine, moving from flawed animal models to advanced tools that test drugs on human cells first.

The Oklahoma CDMO's move to integrate AI and 'high-touch' service isn't just a website refresh; it's a strategic play in a multi-billion dollar market.

Illumina's appointment of Eli Lilly's R&D chief isn't just a new hire; it's a strategic masterstroke signaling a deeper push into drug development.

Kalaris Therapeutics, backed by VEGF pioneer Dr. Napoleone Ferrara, presents early data on its next-gen eye drug. Can TH103's novel science overcome recent development hurdles?

BioMendics secured a key FDA Fast Track designation for its EBS therapy, a strategic move that de-risks development and signals a new era for rare disease treatment.